Expert Q&A on Biosimilar Patent Litigation under the BPCIA | Practical Law

Expert Q&A on Biosimilar Patent Litigation under the BPCIA | Practical Law

An expert Q&A with Kevin E. Noonan of McDonnell Boehnen Hulbert & Berghoff LLP on the key features of the Biologics Price Competition and Innovation Act of 2009 (BPCIA), including the regulatory requirements for biosimilar approval under the BPCIA, the requirements and implications of patent litigation under the BPCIA, and how it differs from the Hatch-Waxman Act.

Expert Q&A on Biosimilar Patent Litigation under the BPCIA

Practical Law Article 0-586-1145 (Approx. 13 pages)

Expert Q&A on Biosimilar Patent Litigation under the BPCIA

by Practical Law Intellectual Property & Technology
Published on 12 Nov 2014 • USA (National/Federal)
An expert Q&A with Kevin E. Noonan of McDonnell Boehnen Hulbert & Berghoff LLP on the key features of the Biologics Price Competition and Innovation Act of 2009 (BPCIA), including the regulatory requirements for biosimilar approval under the BPCIA, the requirements and implications of patent litigation under the BPCIA, and how it differs from the Hatch-Waxman Act.